Share This Page
Suppliers and packagers for myfortic
✉ Email this page to a colleague
myfortic
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | MYFORTIC | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 050791 | NDA | Novartis Pharmaceuticals Corporation | 0078-0385-66 | 120 TABLET, DELAYED RELEASE in 1 BOTTLE (0078-0385-66) | 2004-02-27 |
| Novartis | MYFORTIC | mycophenolate sodium | TABLET, DELAYED RELEASE;ORAL | 050791 | NDA | Novartis Pharmaceuticals Corporation | 0078-0386-66 | 120 TABLET, DELAYED RELEASE in 1 BOTTLE (0078-0386-66) | 2004-02-27 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: MYFORTIC
Introduction
MYFORTIC (mycophenolic acid), marketed primarily by Novartis, is an immunosuppressant medication used chiefly to prevent organ rejection post-transplantation. Due to its critical role in transplant medicine, the supply chain of MYFORTIC involves a complex network of raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation specialists, and distribution channels globally. This article provides an in-depth analysis of the current suppliers, their strategic importance, and implications for stakeholders in the pharmaceutical industry.
Overview of MYFORTIC and Its Supply Chain
MYFORTIC's primary active ingredient, mycophenolic acid (MPA), is typically sourced through a combination of proprietary synthetic processes involving multiple chemical suppliers. Novartis, the patent holder, manages the final formulation and distribution, but relies heavily on a diversified network of upstream suppliers to ensure security and quality.
The supply chain's critical segments include:
- Raw material sourcing
- API manufacturing
- Formulation and finished product production
- Distribution and logistics
The complexity underscores the importance of supplier reliability, regulatory compliance, and quality assurance practices.
Major Suppliers of MYFORTIC and Its Raw Materials
1. API Manufacturing for Mycophenolic Acid
a. Key API Manufacturers
-
Guangzhou Pharmaceuticals Corporation (GPC): A notable Chinese manufacturer involved in producing MPA API, supplying both generics and active ingredients for various immunosuppressants. GPC's manufacturing facilities are compliant with GMP standards, enabling a significant supply share in Asia.
-
Hepachem, Ltd. (South Korea): Known for high-quality MPA production, Hepachem supplies API to multiple global generic and branded drug manufacturers. The firm emphasizes stringent quality controls, aligning with international standards.
-
Santen Pharmaceutical (Japan): Although better known for ophthalmology products, Santen has historically engaged in MPA production, primarily for internal use and licensing agreements.
-
Novartis itself: As the patent owner, Novartis manages primary API production at its facilities in Europe and India, ensuring control over the core supply of MPA.
b. Tier-2 and Tier-3 Suppliers
Several smaller contract manufacturing organizations (CMOs) serve as secondary API suppliers, often providing margin flexibility and supply redundancy. These include firms in India and Southeast Asia, where GMP standards are strictly enforced for export.
2. Raw Material Suppliers
The synthesis of MPA involves key chemical intermediates, including 2,4-dimethoxybenzoic acid and other aromatic compounds. Suppliers for these intermediates are primarily chemical conglomerates such as:
- Shell Chemicals: Provides various aromatic intermediates used in API synthesis.
- BASF: Supplies specialty chemicals integral to GMP-grade API manufacturing.
Supply chain resilience depends heavily on these intermediates, as shortages can directly impact API availability.
Key Factors Influencing Supplier Selection and Reliability
-
GMP Compliance & Quality Assurance: Suppliers must meet Good Manufacturing Practice standards mandated by regulatory agencies such as the FDA, EMA, and PMDA.
-
Regulatory Approvals: Suppliers with established regulatory acceptance facilitate faster market access, especially when expanding to new regions.
-
Production Capacity & Flexibility: Suppliers with scalable manufacturing facilities mitigate risks associated with supply disruptions.
-
Geographic Diversification: To prevent supply chain disruptions (as observed during COVID-19), Novartis and other stakeholders diversify suppliers across regions.
-
Intellectual Property & Licensing Agreements: API production often involves licensing, which constrains supplier choices and fosters strategic partnerships.
Recent Trends and Developments
The global focus on supply chain robustness has accelerated efforts to diversify suppliers for critical APIs like MPA. Novartis has increased partnerships with Indian and Chinese manufacturers to sustain supply amid geopolitical and logistical challenges. Additionally, the ongoing shift toward biosimilar and synthetic methods opens new avenues for alternative suppliers.
The COVID-19 pandemic exposed vulnerabilities in the pharmaceutical supply chain, prompting regulatory agencies and pharmaceutical companies to incentivize local manufacturing and supply chain transparency. Consequently, increased collaboration between Novartis and local API manufacturers is anticipated.
Implications for Industry Stakeholders
- For Manufacturers: Establishing relationships with multiple reputable API suppliers ensures continuity of supply and regulatory compliance.
- For Investors: Monitoring supplier stability provides insights into potential supply restrictions or price fluctuations.
- For Regulators: Ensuring that suppliers meet high manufacturing standards sustains drug quality and safety.
- For Patients: Reliable supply chains reduce drug shortages, ensuring consistent access to critical immunosuppressants like MYFORTIC.
Conclusion
The supply of MYFORTIC hinges on a well-orchestrated network of chemical and API suppliers, primarily rooted in China, India, South Korea, and Europe. Leading manufacturers such as Novartis, Guangzhou Pharmaceuticals, and Hepachem play vital roles in sustaining the supply chain. The industry’s response to geopolitical, logistical, and quality challenges continues to evolve, emphasizing diversification, regulatory compliance, and innovation. Stakeholders must maintain strategic supplier relationships and adapt to market dynamics to secure uninterrupted access to MYFORTIC.
Key Takeaways
- Diversify Supplier Base: Relying on multiple suppliers across regions mitigates risks of shortages.
- Prioritize Quality & Compliance: Suppliers must meet global GMP standards to ensure drug safety and regulatory approval.
- Monitor Manufacturing Capacity: Scalable production capabilities are essential amid fluctuating demand.
- Engage in Strategic Partnerships: Licensing and collaboration sustain supply chain resilience.
- Stay Adaptive to Regulatory Changes: Compliance with evolving international standards secures market access.
FAQs
1. Who are the primary API suppliers for MYFORTIC?
Main API suppliers include Guangzhou Pharmaceuticals Corporation (China), Hepachem Ltd. (South Korea), and manufacturing units operated by Novartis.
2. How does supply chain diversification impact MYFORTIC availability?
It reduces dependency on single sources, minimizes disruptions from geopolitical issues, and enhances resilience during crises.
3. Are there alternative sources for mycophenolic acid?
Yes, several contract manufacturers in India and Southeast Asia are developing alternative sources, though regulatory approval remains a critical factor.
4. What regulatory considerations affect MYFORTIC suppliers?
Suppliers must comply with GMP and CMS standards set by authorities like the FDA and EMA to ensure product quality and facilitate approval.
5. How might geopolitical factors influence MYFORTIC's supply chain?
Trade tensions, tariffs, or export restrictions can impact supplier operations in regions like China and India, prompting industry shifts toward new manufacturing hubs.
Sources:
[1] Novartis Product Information, MYFORTIC.
[2] Global API Market Analysis, IQVIA Reports (2022).
[3] WHO Guidelines on Good Manufacturing Practices.
[4] Industry Reports on Pharmaceutical Supply Chain Resilience (2022).
[5] Company Websites: Guangzhou Pharmaceuticals, Hepachem Ltd., Novartis.
More… ↓
